Gyorgy Keri

Semmelweis University, Hungary

Gyorgy Keri is the CEO and the CSO of Vichem Chemie Research Ltd., the Head of the Signal Transduction Therapy Laboratory at Semmelweis University, and the President of the Rational Drug Design Laboratory Cooperation Research Center. He is a chemist by profession and got his Ph.D. degree in biochemistry in 1976 at Eötvös University of Sciences, Budapest, Hungary, and was a post doc in 1978-1979 with Professor J. Ramachandran, University of California, San Francisco. He was a visiting scientist in the United States 19 times for various time periods on the bases of joint research grants with UCSF and on scientific collaborations with UCSF and Genentech and SUgen. He has founded Biosignal Ltd. in 1992, to utilize and develop his signal inhibiting peptide compound (TT232) which has reached phase II clinical trials and was licensed to Thallion Pharmaceuticals. He has been collaborating with Professor Axel Ullrich (chief scientist of Genetech, MPI, and SUgen) for more than 20 years on developing kinase inhibitors. He was an advisor and a collaborative partner of SUgen Inc. between 1992 and 1999 and Axxima Pharmaceuticals between 1999 and 2006. He was involved in the development of SU101, which has reached phase III clinical trial at SUgen. He has developed the Nested Chemical LibraryTM Technology which is a unique technology of lead finding and optimization in the kinase field. He has also participated in the development of the KinaTorTM technology for selectivity profiling of kinase inhibitors. Moreover, he has received 2 international and 5 Hungarian awards, published 150 scientific papers, and has 65 international patents. He is a Coeditor-in-Chief of Current Signal Transduction Therapy and a member of the editorial board of 4 international scientific journals. He was the Editor of the book: Molecular Pathomechanisms—New Trends in Drug Research by Taylor and Francis. He is participating in 5 FP6/FP7 European programs and is a coordinator of a program about developing novel tuberculosis drugs.

Biography Updated on 12 November 2009

Scholarly Contributions [Data Provided by ]